Skip to main content
SpringerLink
Log in

The clinical potential of Deprenyl in neurologic and psychiatric disorders

  • Conference paper
Deprenyl — Past and Future

Part of the book series: Journal of Neural Transmission ((NEURAL SUPPL,volume 48))

Summary

This article reviews the results of clinical studies with Deprenyl in various neurologic and psychiatric disorders except Parkinson’s disease. Promising results could be observed both in narcolepsy in a dose of at least 20 mg/day in three different trials and in one study of Tourette’s syndrome including attention hyperactivity disorders using an average dosis of 8.1 mg/ day. Controversial results were reported for Alzheimer’s disease. On the one hand significant improvement of cognitive functions was found by various authors. On the other hand in a more recent study no effect on the progression of the disease could be observed. For depression a higher dosage of deprenyl between 30 to 60 mg/day appears to be necessary for effective treatment. No positive results were found in amyotrophic lateral sclerosis and in tardive dyskinesias.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Agid Y, Javoy-Agid F, Ruberg M, et al (1986) Progressive supranuclear palsy: anatomoclinical and biochemical considerations. Adv Neurol 45: 191–206

    Google Scholar 

  • Agnoli A, Martucci N, Fabbrini G, et al (1990) Monoamine oxidase and dementia: treatment with an inhibitor of MAO-B activity. Dementia 1: 109–114

    Google Scholar 

  • Baldessarini RJ (1979) Neurological toxicology of antipyschotic drugs. McLean Hosp J 4:2–19

    Google Scholar 

  • Bamford CR, Montgomery EB Jr, Munoz JE, et al (1993) Postpolio syndrome-response to deprenyl (selegiline). Int J Neurosci 71(1–4): 183–188

    Article  PubMed  CAS  Google Scholar 

  • Bucci L (1987) The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology 91: 104–108

    Article  PubMed  CAS  Google Scholar 

  • Burke WJ, Roccaforte WH, Wengel SP, et al (1993) L-Deprenyl in the treatment of mild dementia of the Alzheimer type: results of a IS-month trial. J Am Geriatr Soc 41(11): 1219–225

    PubMed  CAS  Google Scholar 

  • Campi N, Todeschini GP, Scarzella L (1990) Selegiline versus L-acetylcarnitine in the treatment of Alzheimer type dementia. Clin Ther 12: 306–314

    PubMed  CAS  Google Scholar 

  • Chouinard G, Jones BD, Annable L (1980) L-dopa in neuroleptic induced extrapyramidal symptoms. 35th Annual Convention of Society of Biological Psychiatry of USA, Boston

    Google Scholar 

  • Cohen G, Spina MB (1989) Deprenyl suppresses the oxidant stress associated with increased dopamine turn-over. Ann Neurol 26: 689–690

    Article  PubMed  CAS  Google Scholar 

  • Crow TJ (1980) Molecular pathology of schizophrenia: more than one disease process? Br Med J 280: 66–68

    Article  PubMed  CAS  Google Scholar 

  • Gewirtz GR, Sharif Z, Cadet JL, Sarti P, Gorman JM (1993) Selegiline for neuroleptic-induced Parkinsonism. Pharmacopsychiat 26: 128–129

    Article  CAS  Google Scholar 

  • Goff DC, Renshaw PF, Sarid-Segal O, et al (1993) A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry 33: 700–706

    Article  PubMed  CAS  Google Scholar 

  • Heinonen EH, Lammintausta R (1991) A review of the pharmacology of selegiline. Acta Neurol Scand 136 [Suppl]: 44–59

    Article  CAS  Google Scholar 

  • Hublin C, Partinen M, Heinonen EH, Punkka P, Salmi T (1994) Selegiline in the treatment of narcolepsy. Neurology 44: 2095–2101

    PubMed  CAS  Google Scholar 

  • Jankovic J (1992) Diagnosis and classification of tics and Tourette Syndrome. Adv Neurol 58: 7–14

    PubMed  CAS  Google Scholar 

  • Jankovic J (1993) Deprenyl in attention deficit associated with Tourette’s syndrome. Arch Neurol 50:286–288

    Article  PubMed  CAS  Google Scholar 

  • Jossan SS, Ekblom J, Gudjonsson O, Hagbarth KE (1994) Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis. J Neural Transm [Suppl] 41: 237–241

    CAS  Google Scholar 

  • Knoll J (1989) The pharmacology of selegiline ((−)deprenyl). New aspects. Acta Neurol Scand 126 [Suppl]: 83–91

    Article  CAS  Google Scholar 

  • Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. In: Costa E, Sandler M (eds) Monoamine oxidase — new vistas. Raven Press, New York, pp 393–408

    Google Scholar 

  • Kuritzky A, Zoldan Y, Melamed E (1992) Selegiline, a MAO-B inhibitor, is not effective in the prophylaxis of migraine without aura — an open study. Headache 32(8): 416

    Article  PubMed  CAS  Google Scholar 

  • Lavie P, Wajsbort J, Youdim MBH (1980) Deprenyl does not cause insomnia in parkinsonian patients. Commun Psychopharmacol 4: 303–307

    PubMed  CAS  Google Scholar 

  • Lohr JB (1991) Oxygen radicals and neuropsychiatric illness. Arch Gen Pschiatry 48: 1097–1106

    Article  CAS  Google Scholar 

  • Mangoni A, Grassi MP, Frattola L, Piolti R, Bassi S, Motta A, Marcone A, Smirne S (1991) Effects of a MAO-B inhibitor in the treatment of Alzheimer’s disease. Eur Neurol 31: 100–107

    Article  PubMed  CAS  Google Scholar 

  • Mann J, Gershon S (1980) L-Deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression. Life Sci 26: 877–882

    Article  PubMed  CAS  Google Scholar 

  • Mann JJ, Frances A, Kaplan RD, et al (1982) The relative efficacy of 1-Deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression. J Clin Psychopharmacol 2(sn1): 54–57

    Article  PubMed  CAS  Google Scholar 

  • Mann JJ, Aarons SF, Wilner PJ, Keilp JG, Sweeney JA, Pearlstein T, Frances AJ, Kocsis JH, Brown RP (1989) A controlled study of the antidepressant efficacy and side effects of (−)-deprenyl: a selective monoamine oxidase inhibitor. Arch Gen Psychiatry 46: 45–50

    Article  PubMed  CAS  Google Scholar 

  • Mayer G, Ewert Meier K, Klinik Hephata (1995) Selegiline Hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol 18/4: 306–319

    Article  PubMed  CAS  Google Scholar 

  • Mazzini L, Testa D, Balzarini C, Mora G (1994) An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis. J Neurol 241: 223–227

    Article  PubMed  CAS  Google Scholar 

  • Meltzer HY, Sommers AA, Luchins DJ (1986) The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizphrenia. J Clin Psychopharmacol 6: 329–338

    Article  PubMed  CAS  Google Scholar 

  • Mendis N, Pare CMB, Sandler M, et al (1981) Deprenyl in the treatment of depression. In: Youdim MBH, Paykel ES (eds) Monoamine oxidase inhibitors: the state of the art. John Wiley and Sons, Chichester, pp 171–176

    Google Scholar 

  • Mendlewicz J, Youdim MBH (1983) L-Deprenyl, a selective monoamine oxidase type B inhibitor, and the treatment of depression: a double blind evaluation. Br J Psychiatry 142: 508–511

    Article  PubMed  CAS  Google Scholar 

  • Mitchell JD, Houghton E, Kilshow J, et al (1993) Free radicals, sporadic motor neurone disease and selegiline. Symposium on Neuroprotection and clinical trials in MND/ ALS, Paris (Abstract)

    Google Scholar 

  • Monteverde A, Gnemmi P, Rossi F, Monteverde A (1990) Selegiline in the treatment of mild to moderate Alzheimer type dementia. Clin Ther 12: 315–322

    PubMed  CAS  Google Scholar 

  • Nakamura S, Kawamata T, Akiguchi I, Kameyama M, Nakamura N, Kimura H (1990) Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol 80: 419–425

    Article  PubMed  CAS  Google Scholar 

  • Nieforth KA, Golbe LI (1993) Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol 16/4: 338–346

    Article  PubMed  CAS  Google Scholar 

  • Oreland L, Gottfries CG (1986) Brain and brain monoamine oxidase in aging and in dementia of Alzheimer’s type. Prog Neuropsychopharmacol Biol Psychiatry 10: 533–540

    Article  PubMed  CAS  Google Scholar 

  • Perenyi A, Bagdy G, Arato M (1983) An early phase II trial with l-deprenyl for the treatment of neuroleptic-induced Parkinsonism. Pharmacopsychiat 16: 143–146

    Article  CAS  Google Scholar 

  • Perenyi A, Goswami U, Frecska E, Arata M, Bela A (1992) L-Deprenyl in treating negative symptoms of schizophrenia. Psychiatry Res 42: 189–191

    Article  PubMed  CAS  Google Scholar 

  • Piccinin GL, Finali G, Piccarilli M (1990) Neuropsychological effects of L-deprenyl in Alzheimer’s dementia. Clin Neuropharmacol 13: 147–163

    Article  PubMed  CAS  Google Scholar 

  • Quitkin FM, Liebowitz MR, Stewart JW, McGrath PJ, Harrison W, Rabkin JG, Markowitz J, Davies SO (1984) L-Deprenyl in a typical depressives. Arch Gen Psychiatry 41: 777–781

    Article  PubMed  CAS  Google Scholar 

  • Quitkin FM, Liebowitz MR, Stewart JW, et al (1985) Deprenyl in atypical depressives. I. Clinical efficacy. Proceedings of the International Symposium in Deprenyl. Chinoin, Budapest, pp 115–119

    Google Scholar 

  • Roselar SE, Langdon N, Lock CB, Jenner P, Parkes JD (1987) Selegiline in narcolepsy. Sleep 10(5): 491–495

    Google Scholar 

  • Schachter M, Price PA, Parkes JD (1979) Deprenyl in narcolepsy. Lancet i: 831–832

    Google Scholar 

  • Schneider LS, Olin JT, Pawluczyk S (1993) A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer’s disease. Am J Psychiatry 150: 321–323

    PubMed  CAS  Google Scholar 

  • Sunderland T, Cohen R, Molchan S, et al (1994) High dose selegiline in treatmentresistant older depressive patients. Arch Gen Psychiatry 51: 607–615

    Article  PubMed  CAS  Google Scholar 

  • Tariot PN, Cohen R, Sunderland T, et al (1987a) L-Deprenyl in Alzheimer’s disease. Arch Gen Psychiatry 44: 427–433

    Article  PubMed  CAS  Google Scholar 

  • Tariot PN, Sunderland T, Weingartner H, et al (1987b) Cognitive effects of L-deprenyl in Alzheimer’s disease. Psychopharmcology 91: 489–495

    Article  CAS  Google Scholar 

  • Tatton WG (1993) Selegiline can mediate neuronal rescue rather than neuronal protection. Mov Disord 8: 520–530

    Article  Google Scholar 

  • Thornton C, Dore CJ, Elsworth JD, Herbert M, Stern GM (1980) The effect of Deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man. Psychopharmcol 70: 163–166

    Article  CAS  Google Scholar 

  • Tringer L, Haits G, Varga E (1971) The effect of L-E-280 (L-phenylisopropyl-methyl-propinylamine) in depression. Soc Pharmacol Hungarica, Budapest, pp 111–113

    Google Scholar 

  • Varga E, Tringer L (1967) Clinical trial of a new type of promptly acting psychoenergetic agent (Phenyl-isopropyl-methyl propinyl-HCL, E 250). Acta Med Acad Sci Hung 23: 289–295

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, St. Josef-Hospital, D-44791, Bochum, Germany

    Prof. Dr. W. Kuhn & Th. Müller

Authors
  1. Prof. Dr. W. Kuhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Th. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neurological Clinic, St. Josef Hospital, Bochum, Germany

    W. Kuhn , P. Kraus  & H. Przuntek ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag/Wien

About this paper

Cite this paper

Kuhn, W., Müller, T. (1996). The clinical potential of Deprenyl in neurologic and psychiatric disorders. In: Kuhn, W., Kraus, P., Przuntek, H. (eds) Deprenyl — Past and Future. Journal of Neural Transmission, vol 48. Springer, Vienna. https://doi.org/10.1007/978-3-7091-7494-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-7494-4_8

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82891-5

  • Online ISBN: 978-3-7091-7494-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation